Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Jones, Nick K; Rivett, Lucy; Seaman, Shaun R.; Samworth, Richard J.; Warne, Ben; Workman, Christopher T.; Ferris, Mark; Wright, Jo; Quinnell, Natalie; Shaw, Ashley; Goodfellow, Ian; Lehner, Paul J.; Howes, Rob; Wright, Giles; Matheson, Nicholas J; Weekes, Michael P.

doi:10.7554/elife.68808

Cited by 62 publications

(48 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most European countries, including Italy, are facing a shortage of vaccines. In this situation, all potential second-dose deferral strategies are considered in order to give even partial protection to the highest percentage of the population [ 11 ]. This strategy has not been studied and could expose people to incomplete protection for a long time.…”

Section: Discussionmentioning

confidence: 99%

“…The BNT162b2 mRNA vaccine is administered intramuscularly in two 30-μg doses, 21 days apart [ 9 ]. The clinical trial data is encouraging [ 8 , 10 ], and there is some evidence that even a single dose of BNT162b2 mRNA vaccine is protective against asymptomatic SARS-CoV-2 infection [ 11 ], but more studies are needed regarding the immunogenicity and efficacy of the first dose.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact of the first dose of the BNT162b2 mRNA vaccine on SARS-CoV-2 infections in terms of the prevalence of symptomatic cases, symptom duration, and viral clearance timing. All vaccinated Healthcare Workers (HCWs) with positive RT-PCR by nasopharyngeal (NP) swabs were divided into two cohorts (positive RT-PCR within day 12 and positive RT-PCR between day 13 and day 21 after first dose administration) and compared for the presence and duration of symptoms and the timing of viral clearance. The same variables were evaluated across HCWs with positive RT-PCR within 6 days after first dose administration and non-vaccinated HCWs with positive RT-PCR between 1 October 2020 and 28 February 2021. Eighteen HCWs tested positive on RT-PCR by NP swab from day 1 to day 12 after the 1st dose administration (incidence rate 6.2 × 10−4) and 5 HCWs from day 13 to day 21 (incidence rate 2.3 × 10−4). Symptom duration and viral clearance timing are significantly shorter in the cohort of HCWs with positive RT-PCR 12 days after the first dose of the BNT162b2 mRNA vaccine. The administration of the first dose proved effective in reducing presence, symptom duration, and viral clearance even in HCWs vaccinated for less than 6 days. These results could have implications on public health and post-exposure prophylaxis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Similarly, real-world cohort data have demonstrated efficacy with a single dose of the Pfizer vaccination, resulting in a four-fold decrease in the rate of asymptomatic positive PCR results in health care workers. 45 As described in the above table, real work data from Israel reports estimated effectiveness in preventing death from COVID-19 of 72% (95% CI for days 14 to 20 following the first dose, while effectiveness was 46% for documented COVID-19 infection, 57% for symptomatic COVID-19, 74% for hospitalisation and 62% for severe disease. 27 Using mathematical modelling, a further realworld Israeli study has identified effectiveness for prevention of severe cases and hospitalisation of 82%-83% utilising the Pfizer vaccine, which increases to a 98% reduction following the second dose.…”

Section: Sars-cov-2 Vaccine -Emerging Realworld Datamentioning

confidence: 98%

SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease

et al. 2021

View full text Add to dashboard Cite

Background:The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide.Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions.Aim: This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD.Methods: All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and | 213 PRENTICE ET al.

show abstract

“…Seven of 30 studies investigated VE against asymptomatic SARS-CoV-2 infections [11,[19][20][21][22]31,32] (Table 2).…”

Section: Prevention Of Asymptomatic Infectionmentioning

confidence: 99%

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021

et al. 2021

View full text Add to dashboard Cite

Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people. We report interim results of a living systematic review. We identified a total of 30 studies that investigated VE against symptomatic and/or asymptomatic infection. In fully vaccinated individuals, VE against symptomatic and asymptomatic infections was 80–90% in nearly all studies. Fully vaccinated persons are less likely to become infected and contribute to transmission.

show abstract

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Cited by 62 publications

References 5 publications

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers

SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021

Contact Info

Product

Resources

About